Innoviva, Inc.
INVANASDAQHealthcareBiotechnology
As of Oct 23, 2026 close
- Market cap
- $1.52B
- P/E (TTM)
- 4.25
- Forward P/E
- 2.42
- Dividend yield
- -
- 52-week range
- $17.13$25.15
- Volume (live)
- -
- Avg. volume (3M)
- 895.89K
Innoviva (INVA) Stock Price & Financial Analysis
Innoviva Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $20.51 - $20.94 |
|---|---|
| 52-Week High | $25.15 |
| 52-Week Low | $17.13 |
| Open | $20.88 |
| Volume (last close) | 978.55K |
| Average Volume (3M) | 895.89K |
| Revenue (TTM) | 443.43M |
|---|---|
| Net Income (TTM) | 357.24M |
| Free Cash Flow (TTM) | 188.32M |
| EPS (TTM) | $4.35 |
| Profit Margin | 80.56% |
| Operating Margin | 36.66% |
| Return on Equity (ROE) | 28.97% |
| Debt to Equity | 0.22 |
| Annual Dividend | $0.00 |
|---|---|
| Dividend Yield | 0.00% |
| Payout Ratio | 0.00% |
| Last Dividend Ex-Date | Sep 8, 2015 |
| Market Cap | 1.52B |
|---|---|
| Shares Outstanding | 73.42M |
| P/E Ratio (TTM) | 4.25 |
| Forward P/E | 2.42 |
| Price to Sales (P/S) | 3.42 |
| Price to Book (P/B) | 1.23 |
| EV/EBITDA | 2.03 |
| 50-Day MA | $20.99 |
|---|---|
| 200-Day MA | $21.83 |
| 1-Year Change | +15.33% |
Source: Market prices and company fundamentals. Data as of Oct 23, 2026. Data sources and methodology
Innoviva at a Glance
As of the Oct 23, 2026 close, Innoviva (INVA) has a market capitalization of $1.52B. The stock trades at 4.3× trailing earnings, 2.4× forward earnings and 3.4× sales. Over the trailing twelve months it earned $357.24M on revenue of $443.43M (a 80.6% profit margin) and generated $188.32M of free cash flow. Revenue grew 18.8% year over year.
As of its latest reported balance sheet, it holds $570.39M in cash and securities against $269.66M of debt, a net cash position of $300.73M.
Innoviva does not currently pay a dividend.
The share price is up 15.3% over the past year. At $20.66 (the Oct 23, 2026 close) it sits within its 52-week range of $17.13 to $25.14, below its 200-day moving average of $21.83.
Based on 5 professional analyst ratings from the past 90 days, the consensus is Buy with an average price target of $39.25, 90.0% above the Oct 23, 2026 close.
Frequently Asked Questions About Innoviva
What is the current stock price for INVA?
As of the Oct 23, 2026 close, INVA stock trades at $20.66. The 52-week range is $17.13–$25.15, with a day range of $20.51–$20.94.
What is the P/E ratio for INVA?
As of the Oct 23, 2026 close, Innoviva's trailing twelve-month (TTM) P/E ratio is 4.3, meaning investors pay $4.3 for every $1 of annual earnings. The forward P/E is 2.4, reflecting analyst expectations for future earnings. Innoviva operates in the Healthcare sector.
Does INVA pay dividends?
Innoviva does not currently pay a regular dividend. The company retains its earnings to reinvest in the business. Check the Dividends tab for historical dividend information.
What do analysts recommend for INVA?
Based on ratings from 5 professional analysts over the last 90 days, the consensus for INVA is Buy. The average 12-month price target is $39.25, a 90.0% upside from the Oct 23, 2026 close of $20.66.
What is the market cap of INVA?
As of the Oct 23, 2026 close, Innoviva's market capitalization is $1.52B, classifying it as a small-cap company. Innoviva operates in the Healthcare sector within the Biotechnology industry.